XOMA - XOMA Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
23.90
+0.32 (+1.36%)
As of 3:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close23.58
Open24.10
Bid24.02 x 100
Ask24.05 x 100
Day's Range23.51 - 24.91
52 Week Range3.96 - 24.91
Volume158,466
Avg. Volume188,933
Market Cap181.59M
Beta2.74
PE Ratio (TTM)-3.45
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cubelast month

    ETFs with exposure to XOMA Corp. : September 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to XOMA Corp. Here are 5 ETFs with the largest exposure to XOMA-US. Comparing the performance and risk of XOMA Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Barrons.comlast month

    [$$] Novartis Deal Could Send Xoma Stock to $19

    Xoma (XOMA:Nasdaq) By Wedbush ($11.18, Sept. 5, 2017) We are upgrading our rating on Xoma to Outperform from Neutral and increasing our 12-month price target to $19 from $9. Due to clinical failures, we thought gevokizumab was shelved but recent cardiovascular clinical success with Novartis’ (NVS) canakinumab apparently created strategic value to have more than one anti-IL-1β treatment--prompting Novartis to license gevokizumab and anti-IL-1β. For gevokizumab, Xoma receives $16 million upfront cash and is eligible for up to $438 million in milestones and high single digit to mid-double-digit percentage tiered royalties on sales.

  • Capital Cube2 months ago

    ETFs with exposure to XOMA Corp. : August 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to XOMA Corp. Here are 5 ETFs with the largest exposure to XOMA-US. Comparing the performance and risk of XOMA Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • XOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cube2 months ago

    XOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis XOMA Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of XOMA Corp. – Emergent BioSolutions Inc., Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Pfizer Inc., AbbVie, Inc., Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. (EBS-US, ... Read more (Read more...)

  • Associated Press5 months ago

    Xoma reports 1Q loss

    The Berkeley, California-based company said it had a loss of $2.37 per share. Losses, adjusted to extinguish debt, were $2.30 per share. The drug developer posted revenue of $260,000 in the period. Xoma ...

  • Zacks6 months ago

    XOMA (XOMA) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in XOMA Corporation (XOMA).

  • GuruFocus.com7 months ago

    Xoma Stock Tumbles 3.81% After Earnings Release

    The company was one of the top gainers last week, and investors expected it to report a rise in EPS

  • Associated Press7 months ago

    Xoma reports 4Q loss

    On a per-share basis, the Berkeley, California-based company said it had a loss of $2.89. The drug developer posted revenue of $524,000 in the period. For the year, the company reported that its loss widened ...

  • Investopedia8 months ago

    Xoma Launches $25 Million Registered Offering

    Xoma announced a $25 million registered direct sale offering of common and preferred stock.

  • Investopedia9 months ago

    XOMA Says Its Drug Candidate 358 Is Progressing

    XOMA plans to initiate a children's study for its XOMA-358 drug after early positive results.

  • Benzinga9 months ago

    13 Emerging Biotechs With Catalysts In 2017

    Biotech stocks, which had a torrid 2016, can look ahead to the unfolding year with some hope, although given the quirky nature of the clinical trial outcomes, a recovery is still in question. Wedbush has ...

  • Capital Cube10 months ago

    ETFs with exposure to XOMA Corp. : December 16, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to XOMA Corp. Here are 5 ETFs with the largest exposure to XOMA-US. Comparing the performance and risk of XOMA Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • How XOMA Corp (XOMA) Stacks Up Against Its Peers
    Insider Monkey10 months ago

    How XOMA Corp (XOMA) Stacks Up Against Its Peers

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]